Inmune Bio CEO exercises 9,014 warrants for shares
Inmune Bio, Inc. Chief Executive Officer David J. Moss exercised common stock purchase warrants to acquire 9,014 shares of Common Stock at an exercise price of $1.40 per share in cash.
Rhea-AI Filing Summary
Inmune Bio, Inc. Chief Executive Officer David J. Moss exercised common stock purchase warrants to acquire 9,014 shares of Common Stock at an exercise price of $1.40 per share in cash. Following this transaction, he directly holds 1,294,883 shares of Common Stock. Under a related warrant inducement offer letter, the remaining 50% of his April 2024 Warrants that were not exercised now have their maturity date extended to December 31, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
9,014 shares exercised/converted
Exercise
2 txns
Insider
Moss David J
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| In-the-Money Exercise | Common Stock Purchase Warrant | 9,014 | $0.125 | $1K |
| Exercise | Common Stock | 9,014 | $1.40 | $13K |
Holdings After Transaction:
Common Stock Purchase Warrant — 9,014 contracts (Direct);
Common Stock — 1,294,883 shares (Direct)
Footnotes (1)
- F1. Represents 9,014 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 9,014 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 9,014 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.
Key Figures
Shares acquired via exercise: 9,014 shares
Exercise price: $1.40 per share
Post-transaction holdings: 1,294,883 shares
+3 more
6 metrics
Shares acquired via exercise
9,014 shares
Common Stock acquired through warrant exercise on July 2, 2026
Exercise price
$1.40 per share
Cash exercise price for April 2024 Warrants
Post-transaction holdings
1,294,883 shares
Common Stock directly held by CEO after the transaction
Warrant transaction price
$0.1250 per warrant
Recorded transaction price per Common Stock Purchase Warrant
Remaining warrants new maturity
December 31, 2027
Extended expiration date for unexercised April 2024 Warrants
Original remaining warrants maturity
June 30, 2026
Prior expiration date before Inducement Letter extension
Key Terms
Common Stock Purchase Warrant, April 2024 Warrants, warrant inducement offer letter agreement, exercise price, +1 more
5 terms
Common Stock Purchase Warrant financial
"Represents 9,014 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
April 2024 Warrants financial
"as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter"
warrant inducement offer letter agreement financial
"entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter")."
exercise price financial
"agreed to purchase 9,014 shares of common stock at a reduced exercise price of $1.40"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
maturity date financial
"extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50%"
The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Inmune Bio (INMB) CEO David J. Moss do in this Form 4?
David J. Moss exercised common stock purchase warrants to acquire 9,014 Inmune Bio common shares. The exercise was for cash at $1.40 per share and arose from an inducement letter related to April 2024 Warrants, increasing his direct equity stake.
What warrants did the Inmune Bio (INMB) CEO exercise and at what price?
He exercised 9,014 April 2024 common stock purchase warrants to buy Inmune Bio common stock at an exercise price of $1.40 per share. These warrants originated from April 2024 offerings and were amended in December 2025, then addressed in a later inducement agreement.
What is the warrant inducement offer letter mentioned for Inmune Bio (INMB)?
The warrant inducement offer letter is an agreement where Moss and other April 2024 Warrant holders agreed to exercise a portion of their warrants for cash at $1.40 per share. In exchange, Inmune Bio extended the maturity date for their remaining April 2024 Warrants.
What happens to the remaining April 2024 Warrants held by the Inmune Bio (INMB) CEO?
The remaining 50% of his April 2024 Warrants were not exercised but had their maturity date extended. Under the inducement letter, their expiration moved from June 30, 2026 to December 31, 2027, giving a longer period in which those warrants can potentially be exercised.
Was the Inmune Bio (INMB) CEO’s warrant exercise a buy or sell transaction?
The transaction was an exercise of derivative securities, classified as an acquisition rather than an open-market purchase or sale. Moss converted 9,014 common stock purchase warrants into 9,014 shares of common stock by paying the $1.40 per share exercise price in cash.
AI-generated analysis. How Rhea-AI works. Not financial advice.
